You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is Incruse?

Incruse Ellipta is an inhalation powder used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta contains an active substance called umeclidinium bromide, which belongs to a group of medicines called bronchodilators.

Incruse should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting reliever inhaler (such as salbutamol).

For further information on Incruse Ellipta (umeclidinium) and potential side effects, please see:

Incruse patient information leaflet (PIL)

Incruse Summary of Product Characteristics (SPC)

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies